top of page
Browse by category
Search
MBX Biosciences announces positive phase 1 topline results for MBX 1416 for the treatment of PBH
MBX Biosciences has announced positive results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical...
Turkey bans swallowable gastric balloons
The Ministry of Health in Turkey has announced a ban on swallowable gastric balloons after experts raised concerns about the risks...
Variant Bio and Novo Nordisk sign multi-year research partnership to discover novel targets for metabolic disease
Variant Bio has announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic...
GLP-1 drugs reduce surgery complications in patients with diabetes
People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of...
Younger adults face rising gastric cancer risk
A global study has revealed a disturbing rise in early-onset gastric cancer, a disease once predominantly affecting older adults but now...
New MRI technique identifies heart disease risk from fat composition
Researchers from the University of Virginia's (UVA) Department of Biomedical Engineering are seeking to use magnetic resonance imaging...
Genetically altered fat cells in mice show promise for obesity treatment
Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic polypeptide...
Calorie content influences food choices regardless of obesity status after surgery
Higher calorie foods were preferred among individuals with and without obesity despite similar taste and texture, according to a study by...
Ratioing the resected gastric volume to the number of fired staplers predicts weight loss
Ratioing the resected gastric volume (RGV) to the number of staplers fired (SF) could be used to predict midterm weight loss, according...
Arrowhead initiates phase 1/2a study of ARO-INHBE for obesity
Arrowhead Pharmaceuticals has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA...
Browse by tag
bottom of page